Travel burden associated with rare cancers: The example of Merkel cell carcinoma
Abstract Background There are limited data on the travel burden for cancer patients with rare tumor types, such as Merkel cell carcinoma (MCC). Objective The objective of this study was to understand the travel burden of MCC patients. Methods This study used data from an MCC registry at the Seattle...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2085 |
| _version_ | 1797236880395206656 |
|---|---|
| author | Rahul Jain Joseph Menzin Kristina Lachance Patrick McBee Hemant Phatak Paul T. Nghiem |
| author_facet | Rahul Jain Joseph Menzin Kristina Lachance Patrick McBee Hemant Phatak Paul T. Nghiem |
| author_sort | Rahul Jain |
| collection | DOAJ |
| description | Abstract Background There are limited data on the travel burden for cancer patients with rare tumor types, such as Merkel cell carcinoma (MCC). Objective The objective of this study was to understand the travel burden of MCC patients. Methods This study used data from an MCC registry at the Seattle Cancer Care Alliance (SCCA). All MCC patients enrolled at SCCA with a valid 3‐digit ZIP code were included. Patients were followed up from January 1, 2012 until their last follow‐up, death, or end of data (January 1, 2017). Travel burden was measured by one‐way travel distance to SCCA from each patient's 3‐digit ZIP code. Patient demographics, tumor characteristics, and follow‐up visit were evaluated and stratified by one‐way driving distance of ≤300 and >300 miles. Results A total of 391 MCC patients were included (68% men, mean age = 67 years [±SD = ±11 years], 67% residing in the West, and 70% white). At diagnosis, 53% of the patients had Stage III or IV MCC. Mean one‐way distance traveled by patients was 1,137 (median: 813) miles, and 57% of patients traveled >300 miles. Compared to patients who traveled ≤300 miles, those who traveled >300 miles were more likely to be <70 years old (46% vs 65%; P < 0.001), were diagnosed with advanced stage (III or IV) MCC (46% vs 59%; P = 0.01), had shorter follow‐up in the cancer registry (mean: 509 vs 212 days; P < 0.001), and had fewer visits during follow‐up (mean: 5.2 vs 2.5; P < 0.001). Conclusions In this single cancer center study, the majority of MCC patients trav‐eled long distances to receive expert care. Longer travel distances appeared to be associated with younger age, a more advanced stage of cancer at study entry and fewer in‐clinic visits, suggesting that travel burden may impact timely and adequate patient care for this rare cancer. |
| first_indexed | 2024-04-24T17:10:53Z |
| format | Article |
| id | doaj.art-b0482fd423cc4bd9a7606ce67aa47c20 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T17:10:53Z |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-b0482fd423cc4bd9a7606ce67aa47c202024-03-28T10:30:36ZengWileyCancer Medicine2045-76342019-05-01852580258610.1002/cam4.2085Travel burden associated with rare cancers: The example of Merkel cell carcinomaRahul Jain0Joseph Menzin1Kristina Lachance2Patrick McBee3Hemant Phatak4Paul T. Nghiem5Boston Health Economics BHE Boston MassachusettsBoston Health Economics BHE Boston MassachusettsDivision of Dermatology, Department of Medicine University of Washington Seattle WashingtonBoston Health Economics BHE Boston MassachusettsEMD Serono, Inc. Rockland MassachusettsDivision of Dermatology, Department of Medicine University of Washington Seattle WashingtonAbstract Background There are limited data on the travel burden for cancer patients with rare tumor types, such as Merkel cell carcinoma (MCC). Objective The objective of this study was to understand the travel burden of MCC patients. Methods This study used data from an MCC registry at the Seattle Cancer Care Alliance (SCCA). All MCC patients enrolled at SCCA with a valid 3‐digit ZIP code were included. Patients were followed up from January 1, 2012 until their last follow‐up, death, or end of data (January 1, 2017). Travel burden was measured by one‐way travel distance to SCCA from each patient's 3‐digit ZIP code. Patient demographics, tumor characteristics, and follow‐up visit were evaluated and stratified by one‐way driving distance of ≤300 and >300 miles. Results A total of 391 MCC patients were included (68% men, mean age = 67 years [±SD = ±11 years], 67% residing in the West, and 70% white). At diagnosis, 53% of the patients had Stage III or IV MCC. Mean one‐way distance traveled by patients was 1,137 (median: 813) miles, and 57% of patients traveled >300 miles. Compared to patients who traveled ≤300 miles, those who traveled >300 miles were more likely to be <70 years old (46% vs 65%; P < 0.001), were diagnosed with advanced stage (III or IV) MCC (46% vs 59%; P = 0.01), had shorter follow‐up in the cancer registry (mean: 509 vs 212 days; P < 0.001), and had fewer visits during follow‐up (mean: 5.2 vs 2.5; P < 0.001). Conclusions In this single cancer center study, the majority of MCC patients trav‐eled long distances to receive expert care. Longer travel distances appeared to be associated with younger age, a more advanced stage of cancer at study entry and fewer in‐clinic visits, suggesting that travel burden may impact timely and adequate patient care for this rare cancer.https://doi.org/10.1002/cam4.2085cancer managementclinical observations |
| spellingShingle | Rahul Jain Joseph Menzin Kristina Lachance Patrick McBee Hemant Phatak Paul T. Nghiem Travel burden associated with rare cancers: The example of Merkel cell carcinoma Cancer Medicine cancer management clinical observations |
| title | Travel burden associated with rare cancers: The example of Merkel cell carcinoma |
| title_full | Travel burden associated with rare cancers: The example of Merkel cell carcinoma |
| title_fullStr | Travel burden associated with rare cancers: The example of Merkel cell carcinoma |
| title_full_unstemmed | Travel burden associated with rare cancers: The example of Merkel cell carcinoma |
| title_short | Travel burden associated with rare cancers: The example of Merkel cell carcinoma |
| title_sort | travel burden associated with rare cancers the example of merkel cell carcinoma |
| topic | cancer management clinical observations |
| url | https://doi.org/10.1002/cam4.2085 |
| work_keys_str_mv | AT rahuljain travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma AT josephmenzin travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma AT kristinalachance travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma AT patrickmcbee travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma AT hemantphatak travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma AT paultnghiem travelburdenassociatedwithrarecancerstheexampleofmerkelcellcarcinoma |